top of page



OMR, Euglena, and Leave a Nest produced a standard antibody against the novel coronavirus (SARS-CoV-2) and confirmed the effect in the antibody test system under joint development

Order-made Medical Research Inc. (President: Yasufumi Murakami), Euglena Co., Ltd. (President: Mitsuru Izumo), Leave a Nest Co., Ltd. (CTO: Joe Inoue) have succeeded in producing a chimeric antibody*1 (hereinafter referred to as a standard antibody) that enables estimation of the concentration of anti-SARS-CoV-2 antibody contained in the blood of a subject in the antibody test system for the SARS-CoV-2 that is being jointly developed.

*1 Antibody that combines the variable region of mouse antibody and the constant region of human antibody


The antibody test system for SARS-CoV-2 that we are developing*2 was a qualitative test to detect the antibodies against SARS-CoV-2 in the blood of the subject, but not a quantitative test to estimate the titer of the antibodies.

*2 The results of the test with informed consent were announced at the release on July 6, 2020.


Standard antibody is necessary for a quantitative test to estimate the titer of the antibodies contained in the blood of a subject. Therefore, we have challenged to develop chimeric monoclonal antibodies*3 against SARS-CoV-2 proteins and have successfully obtained the antibodies with sufficient affinity.

*3 A homogeneous antibody that reacts with a specific part of the antigen and is used for antibody test for diagnostic purposes, antibody drugs, etc.


By using the standard antibodies, we re-analyzed the blood samples that we have already tested. As a result, we confirmed the validity of using standard antibody for evaluating antibody titers in our SARS-CoV-2 antibody test system.


We will continue to develop a highly reliable and quantitative antibody test system.


<About euglena Co., Ltd.>

In 2005, we succeeded in establishing the world's first edible mass culture technology for euglena for the first time in the world. A company listed on the First Section of the Tokyo Stock Exchange, which develops and sells functional foods and cosmetics that utilize the microalgae Euglena produced in Ishigaki Island, and conducts research and development for biofuel production.

<About Leave a Nest Co., Ltd>

Based on the principle of "Development of science and technology and contribution to the earth", with a focus on science education, human resource development, R&D, and creation of new businesses, we have partner companies and public institutions around the world and more than 300 Working on a specific project.


<About Order-made Medical Research Inc.>

Launched by Professor Yasufumi Murakami of Tokyo University of Science, established the innovative antibody production technology LIMAXYS method. An antibody drug venture that enables the production of membrane protein antibodies, which has been difficult to produce until now.


- Press Relevant Contacts -

Euglena Corporation Corporate Communication Division

bottom of page